AR060800A1 - Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica

Info

Publication number
AR060800A1
AR060800A1 ARP070101551A ARP070101551A AR060800A1 AR 060800 A1 AR060800 A1 AR 060800A1 AR P070101551 A ARP070101551 A AR P070101551A AR P070101551 A ARP070101551 A AR P070101551A AR 060800 A1 AR060800 A1 AR 060800A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
substituted
unsubstituted
nalk
Prior art date
Application number
ARP070101551A
Other languages
English (en)
Inventor
Philippe Pointeau
Maruta Celso Akio
Francis Barth
Arnaud Rouquette
Lionel Barre
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR060800A1 publication Critical patent/AR060800A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Reivindicacion 1: Compuesto que responde a la formula (1) en la que: - Z representa un grupo N(R3)XR4, N(R3)COOR5 o OCON(R3)R5; - X representa un grupo -CO-, -SO2-, -CON(R6)- o -CSN(R6)-; - R1 y R2 representan cada uno independientemente uno del otro un átomo de hidrogeno o un alquilo (C1-7) o R1 y R2 junto con el átomo de nitrogeno al que están unidos constituyen un radical heterocíclico saturado o insaturado, de 3 a 8 eslabones que puede contener uno o varios otros heteroátomos seleccionados entre un átomo de oxígeno, de azufre o de nitrogeno, estando dicho radical sin sustituir o sustituido con uno o varios grupos alquilo (C1-4); - R3 representa un átomo de hidrogeno o un grupo alquilo (C1-4); - R4 representa: un grupo alquilo (C3-10) sin sustituir o sustituido con un grupo CF3; un radical carbocíclico no aromático en (C3-12), sin sustituir o sustituido o varias veces por sustituyentes idénticos o diferentes seleccionados entre un grupo alquilo (C1-4), hidroxilo, alcoxi (C1-4), alquiltio (C1-4), ciano; un radical heterocíclico de 3 a 8 átomos oxigenado, sulfurado o nitrogenado saturado o insaturado sin sustituir o sustituido con uno o varios sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), hidroxilo, trifluorometilo, alcoxi (C1-4), trifluorometoxi, trifluorometiltio, alquiltio (C1-4), ciano, nitro o por un grupo oxo; un indolilo sin sustituir o sustiluido con un átomo de halogeno o por un grupo alquilo (C1-4), trifluorometilo, hidroxilo, alcoxi (C1-4), trifluorometoxi, trifluorometiltio, alquiltio (C1-4), ciano, nitro; un tetrahidronaftalenilo; un naftalenilo; un benzotiofenilo o un benzofurilo; un fenilo sin sustituir o sustituido o varias veces por sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), trifluorometilo, trifluorometoxi, hidroxilo, alcoxi (C1-4), alquiltio (C1-4), trifluorometiltio, ciano, nitro, alcanoilo (C1- 4), fenilo, un grupo S(O)nAlk, OS(O)nAlk o NR7R8; un benzodioxilo; un fenoximetileno, un 1-fenoxietileno, estando los grupos fenilo sin sustituir o sustituidos una o varias veces por sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), trifluorometilo, trifluorometoxi, hidroxilo, alcoxi (C1-4), alquiltio (C1-4), trifluorometiltio, ciano, nitro, alcanoilo (C1-4), fenilo, un grupo S(O)nAlk, OS(O)nAlk o NR7R8; los grupos metileno o estando el etileno sin sustituir o sustituido una o varias veces por un grupo alquilo (C1-4) o por un cicloalquilo (C3-7); un grupo fenilciclopropilo, estando el grupo fenilo sin sustituir o sustituido o varias veces por sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), trifluorometilo, trifluorometoxi, hidroxilo, alcoxi (C1-4), alquiltio (C1-4), trifluorometiltio, ciano, nitro, alcanoilo (C1-4), fenilo, un grupo S(O)nAlk, OS(O)nAIk o NR7R8; un alquileno (C1-2) sustituido con uno o dos sustituyentes idénticos o diferentes seleccionados entre: (ii) un radical carbocíclico no aromático en C3-12, sin sustituir o sustituido una o varias veces por un grupo alquilo(C1-4); (ii) un fenilo sin sustituir o sustituido con uno o varios sustituyentes, idénticos o diferentes, seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), hidroxilo, trifluorometilo, alcoxi (C1-4), alquiltio (C1-4), trifluorometoxi, trifluorometiltio, alcanoilo (C1-4), ciano, nitro, fenilo, un grupo S(O)nAlk, OS(O)nAlk o NR7R8; un radical heterociclico de 3 a 8 átomos oxigenado, sulfurado o nitrogenado, saturado o insaturado, sin sustituir o sustituido con uno o varios sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), hidroxilo, trifluorometilo, alcoxi (C1-4), trifluorometoxi, trifluorometiltio, alquiltio (C1-4), ciano, nitro; además cuando X representa un grupo -CON(R6)- o -CSN(R6)-, R4 puede representar un grupo alcanoilo (C1-6) o un grupo benzoilo o bencilcarbonilo, estando el grupo fenilo de dichos grupos sin sustituir o sustituido con sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), trifluorometilo, trifluorometoxi, hidroxilo, alcoxi (C1-4), alquiltio (C1-4), trifluorometiltio, ciano, nitro, alcanoilo (C1-4), fenilo, un grupo S(O)nAlk, OS(O)nAlk o NR7R8; R5 representa un fenilo sin sustituir o sustituido una o varias veces por sustituyentes idénticos o diferentes seleccionados entre un átomo de halogeno, un grupo alquilo (C1-4), trifluorometilo, trifluorometoxi, ciano, nitro, alcoxi (C1-4), alquiltio (C1-4), trifluorometiltio, un grupo S(O)nAlk, OS(O)nAlk o NR7R8; R6 representa un átomo de hidrogeno o un grupo alquilo (C1-4); o R4 y R6 junto con el átomo de nitrogeno al que están unidos constituyen un radical heterociclico de 3 a 8 átomos, que contienen o no un segundo heteroátomo seleccionado entre un átomo de oxigeno, de azufre o de nitrogeno, sin sustituir o sustituido o varias veces por un grupo alquilo (C1-4); un grupo alcanoílo (C1-4); un grupo NR7R8 o CONR7R8; un grupo fenilo sin sustituir o sustituido o varias veces por un átomo de halogeno, un grupo alquilo (C1-4), alcoxi (C1-4) o trifluorometilo, alquiltio (C1-4), trifluorometoxi, trifluorornetiltio o un grupo OS(O)nAlk, S(O)nAlk o NR7R8; R7 y R8 representan cada uno independientemente del otro un átomo de hidrogeno, un grupo alquilo (C1-4) o R7 y R8 junto con el átomo de nitrogeno al que están unidos, constituyen un radical heterocíclico saturado de 4 a 8 átomo que puede contener otro heteroátomo seleccionado entre un átomo de nitrogeno, de oxígeno o de azufre; Ar1 y Ar2 representan cada uno independientemente del otro un fenilo sin sustituir o sustituido con un átomo de halogeno, un grupo alquilo (C1-6), alcoxi (C1-6), alquiltio (C1-6), trifluorometilo, trifluorometoxi, trifluorometiltio, ciano, nitro o un grupo S(Q)nAlk, OS(O)nAlk o NR7R8; n representa 0, 1 o 2; Alk representa un grupo alquilo(C1-7); en forma de base o de sal de adicion, así como en forma de hidrato o de solvato.
ARP070101551A 2006-04-14 2007-04-12 Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica AR060800A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0603382A FR2899899A1 (fr) 2006-04-14 2006-04-14 Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
AR060800A1 true AR060800A1 (es) 2008-07-16

Family

ID=37434008

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101551A AR060800A1 (es) 2006-04-14 2007-04-12 Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica

Country Status (18)

Country Link
US (1) US20090203699A1 (es)
EP (1) EP2010492A2 (es)
JP (1) JP2009533400A (es)
KR (1) KR20080108540A (es)
CN (1) CN101421240A (es)
AR (1) AR060800A1 (es)
AU (1) AU2007239344A1 (es)
BR (1) BRPI0710741A2 (es)
CA (1) CA2645961A1 (es)
DO (1) DOP2007000067A (es)
FR (1) FR2899899A1 (es)
IL (1) IL194573A0 (es)
MX (1) MX2008013208A (es)
PE (1) PE20071224A1 (es)
RU (1) RU2008144952A (es)
TW (1) TW200813037A (es)
UY (1) UY30285A1 (es)
WO (1) WO2007119001A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2011281132B2 (en) * 2010-07-20 2014-01-30 Council Of Scientific & Industrial Research Pyridin- 2 - YL sulfanyl acid esters and process for the preparation thereof
GB201103419D0 (es) 2011-02-28 2011-04-13 Univ Aberdeen
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5481005A (en) * 1990-07-31 1996-01-02 Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2856684B1 (fr) * 2003-06-26 2008-04-11 Sanofi Synthelabo Derives de diphenylpyridine, leur preparation et leur application en therapeutique
FR2864958B1 (fr) * 2004-01-12 2006-02-24 Sanofi Synthelabo Derive de n-[(1,5-diphenyl-1h-pyrazol-3-yl)methyl] sulfonamide, leur preparation et leur application en therapeutique.
FR2876691B1 (fr) * 2004-10-18 2006-12-29 Sanofi Aventis Sa Derives de pyridine, leur preparation, leur application en therapeutique

Also Published As

Publication number Publication date
WO2007119001A2 (fr) 2007-10-25
AU2007239344A1 (en) 2007-10-25
IL194573A0 (en) 2009-09-22
WO2007119001A3 (fr) 2007-12-13
RU2008144952A (ru) 2010-05-20
US20090203699A1 (en) 2009-08-13
TW200813037A (en) 2008-03-16
JP2009533400A (ja) 2009-09-17
KR20080108540A (ko) 2008-12-15
FR2899899A1 (fr) 2007-10-19
DOP2007000067A (es) 2007-10-31
CA2645961A1 (fr) 2007-10-25
UY30285A1 (es) 2007-11-30
MX2008013208A (es) 2008-10-27
CN101421240A (zh) 2009-04-29
PE20071224A1 (es) 2008-01-23
EP2010492A2 (fr) 2009-01-07
BRPI0710741A2 (pt) 2011-06-07

Similar Documents

Publication Publication Date Title
AR060800A1 (es) Derivados de aminometilpiridina su preparacion y su aplicacion en terapeutica
AR054799A1 (es) Derivados de oxindol
AR048086A1 (es) Bencenodicarboxamidas insecticidas
AR057705A1 (es) 3-acilaminobenzanilidas insecticidas
AR044874A1 (es) Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica
AR071055A1 (es) Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas
AR067478A1 (es) Compuestos derivados de morfolina pirimidina
AR055878A1 (es) Derivados de ciclopropanocarboxamida
AR054280A1 (es) Derivados de carboxamidas y su empleo en procedimientos de lucha contra enfermedades de plantas y contra hongos nocivos
AR076228A1 (es) Piperidinas sustituidas como antagonistas de ccr3
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR056691A1 (es) Derivados pirrolopirimidina como inhibidores de syk
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
AR067663A1 (es) Derivados heterociclicos de etiloxi amidas, composiciones que los comprenden y usos de los mismos en agricultura u horticultura, como agentes antifungicos.
PE20120773A1 (es) Anillos triciclicos fusionados sustituidos como inhibidores del virus de hepatitis c
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
AR057989A1 (es) Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
AR070255A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparacion, composiciones farmaceuticas que los contienen y su uso en la modulacion de la actividad de 11-beta hd1 (hidroxiesteroide deshidrogenasa de tipo 1)
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas
AR077032A1 (es) Derivados fluorados de aminotriazol
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
AR037901A1 (es) Beta-amino-alfa-cianoacrilatos
AR068778A1 (es) 5, 6 - diarilpiridinas sustituidas en posicion 2 y 3, intermediarios utilizados en su preparacion, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores de cannabinoides cb1.
AR066077A1 (es) Tiadiazoliloxifenilamidinas y su uso como fungicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure